Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing
NCT01324895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 944
Last updated 2012-03-26
Summary
The objective of this study is to compare the efficacy of prokinetics versus antibiotics versus a combination of antibiotics plus prokinetics in the eradication of Small-Intestinal Bacterial Over-Growth Syndrome (SIBO) in those with and without a positive D-xylose Breath Test.
Hypothesis: Patients with SIBO treated with a combination of prokinetics and in particular octreotide and antibiotics will have reduced recurrence rates of SIBO than either therapy given alone.
Conditions
- Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
- Small Bowel Bacterial Overgrowth Syndrome (SBBOS)
Sponsors & Collaborators
-
University of Florida
lead OTHER
Principal Investigators
-
Baharak Moshiree, MD, MS · University of Florida
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2012-03-31
- Completion
- 2012-03-31
Countries
- United States
Study Locations
More Related Trials
-
Proton Pump Inhibitors and Gastrointestinal Symptoms
NCT02054455 ·Status: COMPLETED ·Phase: PHASE4
-
SIBO, Immune Activation, and FGIDs in Children
NCT02872961 ·Status: COMPLETED
-
Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth
NCT03659175 ·Status: UNKNOWN
-
The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study
NCT01829932 ·Status: COMPLETED ·Phase: NA
-
Probiotics in Intestinal Bacterial Overgrowth
NCT02204891 ·Status: COMPLETED ·Phase: NA
-
Metabolomics in Small Intestinal Bacterial Overgrowth
NCT04057560 ·Status: UNKNOWN
-
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
NCT06612411 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
NCT02565654 ·Status: UNKNOWN
-
Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome
NCT01803724 ·Status: UNKNOWN
-
Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)
NCT04309396 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
NCT06676514 ·Status: COMPLETED ·Phase: NA
-
Effect of a Low FODMAP Diet on SIBO Breath Test Positivity
NCT04627727 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
NCT05819281 ·Status: UNKNOWN ·Phase: PHASE2
-
A Novel Probiotic Mixture in Adults With IBS
NCT06610149 ·Status: COMPLETED ·Phase: NA
-
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
NCT04214470 ·Status: WITHDRAWN
-
Analysis of Differences in Small Intestinal Microbiota Structure and Metabolites Between Patients With Irritable Bowel Syndrome and Healthy Individuals
NCT07212569 ·Status: NOT_YET_RECRUITING
-
Rifaximin for the Treatment of Irritable Bowel Syndrome
NCT00259155 ·Status: COMPLETED ·Phase: PHASE2
-
Sucrose Breath Test to Determine Intestinal Permeability in IBS
NCT01674088 ·Status: COMPLETED
-
The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients
NCT02254629 ·Status: COMPLETED ·Phase: PHASE1
-
Small Intestinal Bacterial Overgrowth Obese
NCT02819037 ·Status: COMPLETED ·Phase: NA
-
SH-DS01 on Fecal Metagenomic Stability
NCT04598295 ·Status: COMPLETED ·Phase: PHASE2
-
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
NCT02251483 ·Status: COMPLETED ·Phase: NA
-
Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth
NCT05967871 ·Status: RECRUITING ·Phase: PHASE1
-
The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
NCT02108119 ·Status: COMPLETED ·Phase: PHASE2
-
Atrantil for Intestinal Bacterial Overgrowth
NCT04755673 ·Status: COMPLETED ·Phase: NA